Evidence map›Paper›PMID 20628650›Full record

ArticlePloS one2010

Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.

Sebastian J Padayatty, Andrew Y Sun, Qi Chen, Michael Graham Espey, Jeanne Drisko, Mark Levine

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 145 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 9 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05327348 phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

The Efficacy of Perioperative Parenteral Ascorbic Acid in Reducing Oxidative Stress Among Patients Undergoing Free Flap Reconstructive Surgery: A Prospective Multicenter Randomized Controlled Pilot Trial

TypeinterventionalSponsorUniversity of MalayaRan2022 to 2023Enrolled34ConditionsOxidative Stress, Ischemia-reperfusion InjuryArmsIntravenous Ascorbate, Normal Saline 10 mL Injection
NCT06493370 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

TypeinterventionalSponsorUniversity of Kansas Medical CenterRan2025 to 2030Enrolled48ConditionsBladder CancerArmsIntravenous ascorbic acid/vitamin C
NCT06995586 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.

TypeinterventionalSponsorNicosia General HospitalRan2026 to 2028Enrolled108ConditionsCardio-pulmonary Bypass, Cardiovascular Diseases, Omega-3 Polyunsaturated Fatty Acids, Omega-3 SupplementationArmsVitamin C, Omega 3 PUFA (EPO/DHA), Lignin, Lactulose
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 9 syntheses or guidelines pooled it, 296 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Role of vitamin C in prevention of complex regional pain syndrome after distal radius fractures: a meta-analysis.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2015
    Pooled it
  8. Pooled it
  9. Vitamin C for preventing and treating tetanus.The Cochrane database of systematic reviews · 2013
    Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Review

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sebastian J PadayattyMolecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Andrew Y Sun
Qi Chen
Michael Graham Espey
Jeanne Drisko
Mark Levine
National Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Kansas Medical Center · USNational Institutes of Health · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

backgroundAnecdotal information and case reports suggest that intravenously administered vitamin C is used by Complementary and Alternate Medicine (CAM) practitioners. The scale of such use in the U.S. and associated side effects are unknown. METHODS AND

findingsWe surveyed attendees at annual CAM Conferences in 2006 and 2008, and determined sales of intravenous vitamin C by major U.S. manufacturers/distributors. We also queried practitioners for side effects, compiled published cases, and analyzed FDA's Adverse Events Database. Of 199 survey respondents (out of 550), 172 practitioners administered IV vitamin C to 11,233 patients in 2006 and 8876 patients in 2008. Average dose was 28 grams every 4 days, with 22 total treatments per patient. Estimated yearly doses used (as 25 g/50 ml vials) were 318,539 in 2006 and 354,647 in 2008. Manufacturers' yearly sales were 750,000 and 855,000 vials, respectively. Common reasons for treatment included infection, cancer, and fatigue. Of 9,328 patients for whom data is available, 101 had side effects, mostly minor, including lethargy/fatigue in 59 patients, change in mental status in 21 patients and vein irritation/phlebitis in 6 patients. Publications documented serious adverse events, including 2 deaths in patients known to be at risk for IV vitamin C. Due to confounding causes, the FDA Adverse Events Database was uninformative. Total numbers of patients treated in the US with high dose vitamin C cannot be accurately estimated from this study.

conclusionsHigh dose IV vitamin C is in unexpectedly wide use by CAM practitioners. Other than the known complications of IV vitamin C in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency, high dose intravenous vitamin C appears to be remarkably safe. Physicians should inquire about IV vitamin C use in patients with cancer, chronic, untreatable, or intractable conditions and be observant of unexpected harm, drug interactions, or benefit.

Indexed as

Ascorbic AcidComplementary TherapiesData CollectionHumansInjections, IntravenousUnited StatesUnited States Food and Drug AdministrationAscorbic Acid

Identifiers

PMID20628650
PMCPMC2898816
OpenAlexW2108045872

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.